Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2017

View Archived Issues

Shenzhen Targetrx Biotechnology divulges EGFR inhibitors

TP Therapeutics wins FDA orphan drug designation for lead clinical compound

New GPR40 agonist ID-11014A shows preclinical liver safety and effects on glucose tolerance

Bitopertin shows promise for treating beta-thalassemia-derived anemia

FDA gives orphan drug status to IDN-7314 from Conatus Pharmaceuticals

Mithra enters license and supply agreement with Fuji Pharma for Donesta

Global Blood Therapeutics' GBT-440 obtains EMA PRIME designation

Alma Bio and Delphi Genetics extend plasmid DNA drug alliance

Small-molecule SIK1 inhibitors for topical induction of UV-independent skin pigmentation

Scholar Rock announces plans to develop lead candidate to improve muscle function in SMA

Amicus Therapeutics applies for approval of migalastat in Japan

Opiant Pharmaceuticals licenses drug delivery technology from Aegis

EC grants orphan drug status to Catalyst Biosciences' CB-2679d

H3B-8800 named U.S. orphan drug for acute myeloid leukemia and chronic myelomonocytic leukemia

Sinovac Biotech enters definitive amalgamation agreement

Mateon Therapeutics reports preclinical data on CA4P

Chengdu Suncadia Pharmaceuticals and collaborator patent mu-opioid receptor antagonists

Auspherix discloses gold complexes as antibacterials

Jiangsu Chia Tai Tianqing Pharmaceutical Group divulges elbasvir analogues

Patient enrollment begins in phase II trial of GKT-831 in primary biliary cholangitis

INVAC-1 vaccine safe and immunogenic in first-in-human study

European approval for Zykadia for first-line ALK-positive NSCLC

Minomic advances cancer imaging trial of miltuximab

Savolitinib begins phase III study in papillary renal cell carcinoma

Servier and Transgene partner on application of viral vectorization technology to allogenic CAR-T

Gemphire reports topline data on phase IIb study of gemcabene for HoFH

Bioverativ completes True North Therapeutics acquisition

Pharmaleads reports initial phase I data on PL-265 for neuropathic pain

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...